Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1,3‐Butanediol in Patients With Heart Failure With Reduced Ejection Fraction
Halvor Guldbrandsen(Aarhus University), Kristoffer Berg‐Hansen(Aarhus University), Henrik Wiggers(Aarhus University), Nigopan Gopalasingam(Aarhus University Hospital), Roni Nielsen(Aarhus University), Kristian Hylleberg Christensen(Aarhus University), Oskar Kjærgaard Hørsdal(Aarhus University Hospital)
Cited by 15
Related Papers
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|716
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
|European Journal of Heart Failure|2016|561
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|526
Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
|Journal of the American Heart Association|2017|235
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
|American Journal of Physiology-Heart and Circulatory Physiology|2010|165